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Abstract: Medication adherence is a growing concern for public health and poor adherence to 
therapy has been associated with poor health outcomes and higher costs for patients. Interventions 
for improving adherence need to consider the characteristics of the individual therapeutic regimens 
according to the needs of the patients. In particular, geriatric and paediatric populations as well as 
dermatological patients have special needs/preferences that should be considered when designing 
drug products. Patient Centric Drug Product Pharmaceutical Design (PCDPD) offers the 
opportunity to meet the needs and preferences of patients. Packaging, orodispersible formulations, 
fixed dose combinations products, multiparticulate formulations, topical formulations and 3D 
printing are of particular relevance in a PCDPD process. These will be addressed in this review as 
well as their impact on medication adherence. 
Keywords: adherence; fixed dose combinations; patient centric pharmaceutical drug product 
design; 3D-printing 
 
1. Introduction 
1.1. Taxonomy 
During the last four decades of adherence research, different definitions of the process of 
deviating from recommended treatment have been employed. The terms “adherence” and 
“compliance” have been used synonymously in the literature; however, the term adherence has 
gained popularity in recent years as it implies a more mutual and dynamic interaction between 
patients and health care providers and emphasizes the importance of medication-taking behaviour. 
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While, the use of the term compliance, which implies that the patient has a passive role in the process 
of medication taking, has diminished [1]. Due to this heterogeneity in the definitions being used 
across scientific literature, it was necessary to obtain a consensus on the terminology and develop a 
taxonomy of adherence. The ABC project (Ascertaining Barriers to Compliance) has recently 
developed an adherence taxonomy which provides concise and adequate definitions to serve the 
needs of both clinical research and medical practice [1,2]. 
Medication adherence has been defined as an active, cooperative and voluntary participation of 
the patient in following recommendations from a healthcare provider [1]. This multifactorial 
behaviour encompasses three critical steps (Figure 1): 
• Initiation, which defines the moment that the patient takes the first dose; 
• Implementation, which is the extent to which a patient’s actual dosing corresponds to the 
prescribed dosing regimen, from initiation until the last dose; 
• Persistence, which is the length of time between initiation and the last dose. 
 
Figure 1. Ascertaining Barriers to Compliance (ABC) taxonomy of medication adherence describing 
its three key steps. Adapted of reference [1]. 
Moreover, the ABC taxonomy clearly distinguishes between procedures that describe actions 
through routines that have been established (medication adherence and management of adherence) 
and the sciences that address those procedures (adherence-related sciences) [2]. The terms 
concordance and persistence have also been used to define some patients’ medication-taking 
behaviours. Concordance implies that the patient and the healthcare professionals came to an 
agreement about the treatment that the patient should follow, acknowledging that they may have 
different points of view, while persistence relates to the time interval between the first and the last 
dose of medicine prescribed [1–4] 
1.2. Impact on Public Health 
Adherence to medication is widely recognized as an increasingly relevant issue to healthcare 
systems as poor adherence to therapy is associated with negative health outcomes and higher patient 
costs. Unfortunately, this aspect is broadly underestimated in real world practice and by patients [5]. 
Adherence to therapy is especially important for chronic diseases’ management, diseases also 
known as noncommunicable diseases (NCDs). As defined by the World Health Organization (WHO), 
NCDs involves “health problems that require continuous treatment over a period of time from years 
to decades.” Approximately 80% of people over 65 suffer from heart failure, respiratory failure, sleep 
disorders, diabetes, obesity, depression, dementia, hypertension, which often occur simultaneously 
in the same individual [6]. Cardiovascular diseases account for most NCDs deaths, (17.9 million 
people annually), followed by cancers (9.0 million), respiratory diseases (3.9 million) and diabetes 
(1.6 million) [7]. In 2020, NCDs will represent about 80% of all diseases in the world, for which about 
70–80% of resources will be committed globally.  
Several studies have shown that adherence to chronic therapies is far from expected, with 
approximately 50% of patients not taking their medications as prescribed [8–11]. A recent cross-
country European study showed that the proportion of treatment discontinuation for NCDs was 
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55.63% for antihyperlipidemics, 60.24% for antiosteoporotics and 46.80% for oral antidiabetics [8], 
within a year. The prevalence of non-adherence in patients suffering from NCDs is higher in 
developing countries given the scarcity of health resources and inequalities in access to health care. 
The patient population at greatest risk of nonadherence is older patients with polytherapy [12]. 
Multimorbidity is increasingly present among older populations, increasing the complexity of the 
therapeutic regimen for all stakeholders and ultimately impacting negatively on health outcomes 
[13,14]. Furthermore, there is an alarming lack of evidence about treatment of patients with multiple 
concurrent chronic diseases [15,16].  
Interesting results are reported in a recent analysis conducted by the IMS (Institute for Health 
Care Informatics), which estimated the economic impact of the use of inappropriate drugs in 186 
countries [17]. The study considered six NCDs of high social impact such as diabetes, osteoporosis, 
heart failure, HIV, hyperlipidaemia, hypertension, estimating at approximately 300 billion dollars 
cost of using non-optimal drug therapies. It showed that two thirds of these costs are attributable to 
approximately ten million avoidable hospitalizations, equivalent to about 140 billion dollars. In 
particular, the issue causing highest cost was nonadherence to therapy, with a value of almost 50% 
of the total. The WHO estimates that the cost of nonadherence to drug therapy amounts to 125 million 
euros per year in Europe, including costs from avoidable hospitalizations, nursing home admissions 
and premature deaths. A study by Sokol et al., 2005, related to four NCDs including diabetes, showed 
that a high level of adherence to therapy in diabetes is associated with lower costs related to illness 
and lower costs of hospitalization [18]. Although adherence can lead to increased pharmacy costs, 
total health care cost is reduced due to reductions in hospitalization rates’ [19]. Hospitalization is the 
largest component of medical costs, so it is likely that the changes in hospitalization risk are the 
primary driver of the cost savings observed at higher levels of adherence. 
1.3. Determinants of Non-Adherence 
Multiple factors can influence low levels of adherence to medications. Based on WHO 
recommendations, the causes of non-adherence are classified into five main dimensions: 
‘socioeconomic factors, health care and system-related factors, therapy-related factors, condition-related factors 
and patient-related factors’ [20–22]. A review of systematic reviews by Kardas et al. identified and 
classified the determinants of patient adherence per the ABC Adherence Taxonomy using the WHO 
5 factor model. The review found that socioeconomic factors, such as family and social support, 
employment status, cost of drugs and/or treatment influence adherence. Furthermore, although non-
adherence has often been perceived as the fault of patients, there was evidence that healthcare system 
factors, such as access to healthcare, unclear information about drug administration, as well as poor 
provider-patient relationship may have an important impact on adherence. Low adherence was also 
related to the condition and the asymptomatic nature of the disease, as well as disease severity [23]. 
Therapy-related factors, such as the complexity of the therapeutic regimen, duration, past failures, 
therapeutic changes or adverse events and factors related to the patient such as forgetfulness, beliefs, 
knowledge and/or skills inadequate to the management of therapy and misunderstanding 
instructions for treatment, were also found to strongly impact on adherence [24]. Another systematic 
review identified almost 800 individual factors, among which frequent dosing, a high number of 
prescribed medications, drug formulation or poor taste, were found to be related to the 
implementation component of adherence behaviour using the WHO 5 factor model [23,25]. Therapy-
related factors, such as patient (un) friendly regimes have also been shown to influence older patients’ 
beliefs and concerns about their treatment, which in turn indirectly influences their adherence [26]. 
Patient concerns about their medication have been shown to increase with the extent to which the 
medications interfere in conducting day to day activities or social events, leading to non-adherence 
[27].  
Research to date indicates that medication non-adherence is affected by multiple determinants 
and many of these determinants are related to each other. Moreover, it is increasingly evident that 
adherence, as a process and the determinants of adherence have to be assessed over time and not just 
at one evaluation time point (drug discontinuation) [28,29]. To develop effective interventions to 
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increase medication adherence it is important to focus on determinants that are modifiable and can 
be identified and targeted for change. Interventions for the improvement of therapeutic adherence 
should not only focus on the clinical aspects of the treatment but consider the characteristics of the 
individual therapeutic regimens according to the needs of the patients, in order to be effective. Many 
of the adverse health outcomes associated with non-adherence may in fact be preventable, if 
measures are taken to address the therapy-related determinants of non-adherence and optimize 
medication-taking ability. 
2. Patient Centric Pharmaceutical Drug Product Design: Defining Target Product Profiles for 
Special Populations  
Patient centric pharmaceutical drug product design (PCDPD) can be defined as the “process of 
identifying the comprehensive needs of individuals or the target patient population and utilizing the 
identified needs to design pharmaceutical drug products that provide the best overall benefit to risk 
profile for that target patient population over the intended duration of treatment” [30]. The patient 
centric drug product design process starts with a target drug product and a patient profile 
considering the patients’ context. Understanding patient preferences and needs regarding treatment 
features is a key element of the patient centric design process. The different patient factors (Table 1) 
should be considered and prioritized to achieve a more universal design, suitable for the broadest 
patient population [31]. 
Table 1. Patient-related characteristics relevant for patient centric pharmaceutical drug product 
design (adapted from References [30,32]). 
Patient-Related Characteristics Examples 
Age Organ and body functions, socioemotional status 
Visual impairment Blindness 
Motoric impairment Arm mobility, difficulty walking, manual dexterity 
Swallowing impairment Dysphagia 
Cognitive impairment Memory loss, dementia 
Poor hand sensitivity Control of movement and strength 
Loss of hearing  
Dentition  
Health literacy  
Psychological distress Negative perception, depressive disorders 
Disease state Comorbidities, disease disability 
PK/PD Renal and hepatic clearance 
Psycho-social issues Way of living, Employment status, access to caregivers 
Drug product in the context of patient centric design is considered the presentation of the 
treatment to the end-user (patient/care giver/health care provider) which includes the dosage form, 
formulation, dose, dosing frequency, packaging (primary, secondary and tertiary), medical device, 
dosing devices and instructions for use (Table 2). Although increased development costs can arise in 
the implementation of PCDPD, the involvement in the early stages of the design process of 
pharmaceutical technologists with good fundamental knowledge on dosage forms and development 
and practical experience on industrial-scale manufacturing can represent an essential contribution to 
the constrain of costs. 
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Table 2. Product-related characteristics relevant for patient centric pharmaceutical drug product 
design (adapted from References [30,32]). 
Product-Related Characteristics Examples 
Route of administration Oral, inhalation, rectal, vaginal, dermal, parenteral 
Product strength concentration  
Type of dosage form Tablet, oral solution, ointment 
Site of dermal application Arm, feet, back 
Appearance Product size, shape, colour, embossing 
Swallowability 
Related to tablet size, shape, coating/waxing, 
liquid viscosity, mouth feel, Taste 
Dose to therapeutic effect Number of tablets, total volume of liquid 
Dosing regimen Dosing frequency, duration of treatment 
Packaging Inner/outer, labelling 
Container closure system   
Dosing and administration devices Syringes, applicator 
Any handlings to be conducted prior to use Opening capsules, measuring liquids, mixing 
Instructions for use Complexity 
Caregiver assistance  Injections 
Integrating these characteristics in the design process helps achieving a drug product adapted 
to the needs and preferences of a target patient population. Some populations present particular 
complexity with respect to medication adherence and will be addressed below. 
2.1. Elderly 
The life expectancy in developed countries has grown in the last decades, increasing the 
proportion of older people with respect to the total population. In addition, the development of novel 
pharmacological treatments has reduced disease mortality and increased the number of illnesses that 
can be controlled by chronic therapies. Also, there has been a shift from inpatient to outpatient 
settings across various areas, for example, neoplastic diseases. As a consequence, the proportion of 
older patients that receive more than one medicinal product each day has significantly increased with 
respect to the past. 
This demographic change has pushed manufacturers to design and produce medicinal products 
based on the biopharmaceutical features of the elderly [33]. Indeed, their health is generally affected 
by a gradual decline of motor function (e.g., dysphagia, trembling hands, reduced flexibility), 
cognition (e.g., impaired cognition, dementia) and sensory acuity (e.g., impaired vision, hearing loss). 
The efficacy and safety profiles of a medicinal product can be altered in the elderly population with 
respect to adults. Both pharmacokinetics and pharmacodynamics of an active pharmaceutical 
ingredient (API) are affected by ageing. For example, the distribution and the metabolism of an API 
can be prejudiced by reduced renal and hepatic functions. Its biodistribution can be altered by the 
changes in the ratio of human body surface area to body weight and the percentage of fatty mass. On 
the other side, the use of specific excipients (e.g., phosphate salts) can overload the renal function in 
older patients who have already been compromised [34].  
Despite these peculiarities, the elderly have not been generally recruited, contrary to younger 
adults, into the clinical studies carried out to obtain a marketing authorization for medicinal products. 
To overcome this limitation, European Medicines Agency (EMA) released in 1994 the guideline “ICH 
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E7–studies in support of special populations: geriatrics,” in which the agency stressed, for the first 
time, the need to recruit patients aged 65 years or older into the clinical trials. In the following years, 
the EMA released additional guidance to applicants promoting more accurate classification criteria 
of the recruited patients, clinical endpoints and tools that can be used to characterize the physical 
frailty of the older patient [35,36].  
Since the decline of motor and sensory function of the elderly, an increased risk of medication 
errors and poorer adherence to the pharmacological therapies are observable in the real world due 
to difficulties in swallowing and handling the drug products [33,37]. As a consequence, several 
aspects have to be considered in the quality target product profile of a drug product intended to be 
administered in older people [38].  
As reported in Figure 2, the pharmaceutical development of an elderly-centric drug product 
should be based on a holistic approach. This should include not only attributes with a strong impact 
on the biopharmaceutical performances of the drug product but also those with an influence on the 
adherence of the patients, such as the handling and dosing. In this light, the use of multi-compartment 
medication devices has been demonstrated to be effective in supporting older patients in their daily 
regimens and in improving clinical outcomes [39,40]. Indeed, such tools permit the patient/caregiver 
to organize in advance the medicines to take in a specific day period (e.g., morning, evening) or day 
of the week, reducing the risk of medication errors and simplifying the actions that patients have to 
do for medicine administration. A proper design of the packaging, labelling and the leaflet 
information are also important aspects to be considered in the development of a patient centric drug 
product for the elderly. The design, the fonts and the other graphical aspects of both the packaging 
and the leaflet should be designed to be readable by a patient with impaired vision in order to 
facilitate the adherence and reduce the risk of misuse or medication errors [41]. For example, it should 
be preferred not coloured standard fonts, high dark/light contrast and point sizes higher than 12 [42]. 
Moreover, the leaflet should include specific information for the elderly (e.g., drug interaction 
information in the older population). 
 
Figure 2. Target product profile of medicinal product intended to be used by the elderly. 
Finally, the development of fixed dose combinations (FDCs) seems desirable, especially for 
multimorbid patients, in order to reduce the medicines that have to be taken by the patients and to 
improve adherence to pharmacological therapies [43]. 
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2.2. Paediatric Population 
Paediatric patients are another special population that needs patient centric medicinal products. 
As well as geriatrics, the majority of medicinal products available on the markets have not been 
indicated for paediatric patients since the clinical trials performed in the pre-authorization stage of 
the product generally do not include children. This lack of information is due to several causes 
including ethical issues related to testing on children.  
In 2007, the European Union released a Regulation to assure a better benefit/risk balance for 
medicinal products with paediatric indications and to increase the availability of age-appropriate and 
paediatric-centric medicines on the market [44]. Among the innovations introduced by Regulation 
No 1901/2006, it is noteworthy the upgrade of regulatory requirements to obtain the marketing 
authorization with a paediatric indication. In particular, applicants should provide a paediatric 
investigation plan (PIP), which should include details of the timing and measures proposed to 
demonstrate the quality, safety and efficacy of a medicinal product in paediatric populations. In the 
following years, the EMA released several guidelines to support applicants in the pharmaceutical 
development [45] and in the clinical trials of paediatric medicinal products [46,47]. The following 
aspects should be considered to define the quality target product profile of a paediatric medicine: 
patient age and its developmental physiology, the peculiar characteristics of the diseases to be treated 
in the children, the route of administration, the dosing regimen, the maximum duration of the 
therapy, the age-associated activities of children (e.g., school, nursery), the environment or setting 
where the product is likely to be used (e.g., hospital or community), the caregivers’ characteristics 
and their behaviour. All these aspects should be considered in order to assure good patient 
acceptability. 
The scenario is even more complicated considering that many diseases are peculiar of childhood. 
For example, febrile seizure affects only children ranging for 6 months to five years old. Bronchiolitis 
is a typical virus infection of the small airways in the lungs that occurs in children less than two years 
of age. The otitis is frequent in children since children have a different anatomical conformation of 
the eustachian tube compared to adults facilitating bacterial infections [48]. 
Therefore, the features of a paediatric-centric drug product change as a function of the age of the 
patient and, the anatomical, functional, physiological developmental stage of body. Indeed, infant 
body anatomy and physiology are significantly different from those of children, adolescent (<18 
years) or adults. For example, the ability to swallow foods and medicines in infants is lower than in 
children and adolescents [49]. In this context, one of the most relevant key aspects to be considered 
in pharmaceutical development is the selection of proper dosage forms based on the target 
population age [50]. Oral liquid dosage forms with a low dosing volume and rapidly dissolving mini-
tablets (diameter 2 mm) can be preferable in infants, whereas immediate release mini-tablets with a 
diameter of 2 mm, oral powders, granules (administered with soft or semisolid food) can be 
administered to young children from 6 months. Mini-tablets with 4-mm diameter are suitable for 
children older than 1 year. Since young children cannot swallow conventional-sized tablets intact 
until 3 or 6 years, immediate and modified released tablets are not considered suitable for such 
patient populations. On the contrary, tablets and capsules were better accepted than other solid oral 
dosage forms by school children and adolescents, due to faster ingestion [51]. However, small tablet 
diameter (<10 mm) or capsule size (<Size #0) are better preferred by school children than adolescents. 
Organoleptic properties, such as product appearance, smell and texture may also affect adherence 
[52]. In this light, the visual appearance of the product should be pleasant enough for the young 
patient but not too attractive to promote the misuse of medicinal products. As well, the taste and 
mouthfeel of the product should be optimized for the paediatric population to find a balance between 
the masking of the unpleasant taste of an API and a low attractiveness of the product to avoid 
accidental intake because of the patient exchanges the medicinal product as a candy [53,54]. 
Besides the dosage form, the API salts and excipients should also be carefully evaluated during 
pharmaceutical development. The API salts should be selected to assure an acceptable bioavailability 
considering the physiological developmental stage of the patient. As an example, the solubility of 
API in liquid dosage forms should be enhanced to avoid the administration of high dose volume. For 
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excipients, their risk assessment of the paediatric exposure should be reconsidered. Indeed, the safety 
profile of an excipient in children cannot be extrapolated tout court from adults due to the different 
physiological developmental stage and the possible immaturity of the children organ and body 
systems [45]. Consequently, safe excipients in adults can be toxic to infants or children or cause 
sensitization or allergies. For example, the use of preservatives in paediatric medicinal products 
should be carefully evaluated. Some studies have demonstrated that parabens (e.g., propyl paraben) 
may interfere with the physiological development of reproductive organs in animal models. As a 
consequence, wherever possible such excipients should be avoided for paediatric formulations. As 
well, the use of benzyl alcohol in preparations intended to be administered to children up to 3 years 
old should be carefully evaluated and, preferentially avoided, due to their immature metabolism [55]. 
In general, age-associated safe levels of exposure are available for many of them. If robust exposure 
data do not exist, a conservative approach has been promoted by the EMA to preserve the health of 
young patients. 
As outlined above, the dose definition (including the use of specific administration/dosing 
devices) and its frequency are other aspects that can impact on the acceptability of a medicinal 
product. In outpatient paediatrics, the dosing errors are frequent in children weighing less than 35 
kg or in children under 4 years [56]. In the majority of the cases, the dose for children under 4 years 
should be adapted according to the patient weight. In this context, if the caregiver is not properly 
trained, the risk of medicines’ overdoses or underdoses increases. Therefore, the availability of dosing 
devices and clear instructions for caregivers is important to facilitate patient adherence and avoid 
medication errors. Taken together all the above-mentioned aspects, a target product profile can be 
proposed for paediatric drug products (Figure 3). 
 
Figure 3. Target product profile of medicinal product intended to be used by paediatric patients. 
When a paediatric dose of the drug product is not available on the market, the only possibility 
to treat children is to tailor the dose by slitting, breaking or crushing a tablet or a capsule (e.g., 
clobazam capsule for seizures, propranolol tablet for infantile hemangiomas) [57]. In many cases, 
these procedures are off-label treatments, since it is frequent that the starting medicinal product has 
not been tested and authorized to be used in children. Such procedure can result in the administration 
of inaccurate dosing, as well as losing specific benefits of certain dosage forms (e.g., slow release 
tablets) [57]. To minimize these errors, the design of a proper device on the basis of the shape and 
size of medicinal products is essential to help caregivers in dosing the medicinal products to assure 
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the reproducibility of dose assumed [58]. Another possible strategy to overcome the unavailability of 
industrial medicinal product or strength for the paediatric population is the compounding of patient-
specific extemporaneous preparation in a pharmacy setting [59]. In this context, the quality, safety 
and efficacy of the compounded preparations have been assured by the cooperation between 
physicians and community/hospital pharmacists. In particular, the product quality is assured by the 
pharmacist professionalism and by procedures to assess the risks connected with the compounding 
of the preparation based on its target profile. In some cases, health authorities of European Countries, 
released monographs for specific paediatric preparations (e.g., British Pharmacopeia, Czech National 
Formulary) to support the prescribing and compounding activities of physicians and pharmacists 
when industrial products are not available. In this context, strong cooperation between 
pharmaceutical technologists and regulatory authorities is important to design and develop 
standardized formulations with suitable biotechnological performance and physicochemical stability 
to improve the quality of the compounded preparation.  
Finally, the regulatory agencies states that all the information and use instructions should be 
provided to patients in a clear way to assure correct and full administration of the medicinal product 
and to minimize the risk of medication errors [45,56]. On one side, the labelling design and the 
readability of the leaflet are key aspects to be considered to support young patients, especially in the 
case of over-the-counter products and caregiver in the correct use of the medicinal products. The 
inclusion of cartoons in the leaflet can be advantageous to improve the comprehension of 
patient/caregiver regarding the administration procedures (e.g., how to split a tablet or to dose a 
syrup). On the other side, if administration/dosing devices have to be used, healthcare professionals 
should train properly the patients and their families to avoid dosing errors. 
2.3. Dermatological Patients 
Dermatological diseases are very common [60]. Different treatment modalities are available and 
topical treatments are frequently used. Adherence is typically low for topical treatments [61,62]. 
Patient, treatment and disease factors have been appointed to justify poor adherence. Regarding 
treatment, poor acceptability of the topical vehicles and staining of clothes have been reported by 
patients with chronic skin disorders as barriers to optimal treatment adherence. For the particular 
case of topical medicines, some patient needs can be identified. For instance, patients with 
impairment of motoric function (e.g., rheumatoid arthritis) might be unable to open closure systems, 
squeeze the tubes, rub the formulations onto the skin or reach less accessible areas. When skin barrier 
is damaged, such as in atopic dermatitis or highly inflamed, as in severe psoriasis, avoiding friction 
deserves special attention.  
Patient preferences also vary according to the dermatologic condition being treated [63] and 
anatomic location of lesions. The physical form has been shown to influence patient preference. For 
example, acne patients tend to prefer washes, creams and lotions; patients with atopic dermatitis 
prefer creams; and psoriasis patients prefer creams, ointments and foams (particularly for the scalp) 
[63]. Specific attributes of topical products were also analysed for psoriasis patients with the three 
attributes more valued by patients being—to allow dressing shortly after application, good 
moisturizing properties and use only once daily [64]. These data, if confirmed in a large population, 
can be largely useful to guide PCDPD. When administration/dosing devices are associated with the 
drug product, user instructions should be clear and healthcare professionals should educate the 
patients and their caregivers about their correct use. A standard target product profile can be 
proposed for medicinal products for dermatological patients (Figure 4). 
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Figure 4. Target product profile of medicinal products intended to be used by dermatological patients. 
3. Patient Centric Pharmaceutical Drug Product Design: The Impact on Medication Adherence 
Translating patients’ preferences and needs into the design of a drug product is the cornerstone 
of PCDPD. A recent literature review identified only 45 studies focusing on patients’ preferences for 
pharmaceutical preparations [65]. Of these, only 35 investigated dosage form design and 11 
exclusively assessed dosage forms for the oral route. Noteworthy, very few studies have examined 
patient’s preferences for shape, size and colour of solid dosage forms [66,67], which are very 
commonly used for the treatment of NCDs. Besides conventional solid dosage forms such as tablets, 
a wide spectrum of dosage forms can be designed and manufactured by the pharmaceutical industry. 
When implementing a PCDP design some drug products emerge more frequently as better 
adapted to promote adherence. These will be addressed with more detail focusing on their impact on 
medication adherence. 
3.1. Packaging 
Several packages have been designed to meet patient needs, like helping to remember when to 
take the medication or assist reading the labels, for instance by using braille inscription. Dose 
dispensing devices (e.g., inhalers) can be also included in the packages to ease the administration. 
For topical treatments, applicators that ease the application, avoiding using hands are already on the 
market (sometimes called “no mess applicators”). Drummond et al. have reviewed preferences for 
packaging design and found that wing top and screw cap openings, push-through blisters and 
suppositories with a slide system were favoured. Child-resistant containers were considered difficult 
to handle by specific patient populations [65]. 
Different packaging options have been designed with the aim to promote adherence including 
multidose dispensing systems (MDDS) [68], calendar packaging [69], pill boxes (also called multi-
compartment containers/multi-compartment compliance aids-MCAs), blister packaging (prepared 
by professionals) and bubble packages [70].  
However, their impact on adherence is still poorly understood. Meta-analysis findings from a 
systematic review support the use of packaging interventions (pill boxes or blister packs) to 
effectively increase medication adherence with a 71% adherence rate reported in the treatment group 
compared to a 63% adherence rate in the control group [40]. A few reports have also emphasized a 
positive effect on adherence of multi-dose dispensing systems (MDDS) [71] calendar packaging [69] 
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collectively suggest that packaging interventions could be helpful as part of a combination strategy 
for adherence promotion, especially for polymedicated patients. 
3.2. Fixed Dose Combinations (FDCs) 
Fixed combination medicinal products offer the opportunity to simplify drug administration. 
Fixed dose combination (FDC) has been developed to reduce the pill burden for patients. By reducing 
overall pill burden and simplifying medication regimens, fixed combinations have been shown to 
improve medication adherence and persistence in several studies [32,43,72,73]. European regulatory 
authorities consider fixed combinations as “a particular technical or technological processing of 
therapeutically active substances in order to allow it to be administered to the patient in the simplest, 
safest and most effective way” [74]. Along with lower pill burden, FDCs often lower the costs of 
treatment, due to the use of inexpensive, generic compounds [75]. Despite this, FDCs do not follow a 
simplified procedure for marketing authorization. If the combination of the APIs is well-established 
for a specific therapeutic indication in the clinical practice, preclinical and clinical studies required 
for the marketing authorization to assess the combination safety and efficacy can be significantly 
reduced. In general, bioequivalence studies between the fixed combination products and the single 
drug products are accepted if no specific pharmacokinetics or pharmacodynamics interaction are 
expected. Alternatively, the marketing authorization holders of a fixed combination medicinal 
product have to provide the preclinical and clinical data to support the therapeutic indication. If the 
fixed combination contains approved APIs not approved as combination therapy or one or more New 
Active Substances, detailed preclinical and clinical data have to be provided [74].  
Today, numerous FDCs exist on the market and are widely recognized as safe and effective 
[43,73,76]. For this reason, many chronic conditions can benefit from this kind of therapeutic 
approach to reduce pill burden, such as dyslipidaemia, atherosclerosis, hypertension, osteoporosis, 
heart failure, post myocardial infarction, angina, type 2 diabetes, chronic obstructive respiratory 
disease and HIV (Table 3). 
Table 3. Fixed dose combination for the treatment of chronic conditions. 
Condition Fixed Dose Combinations  Year of Marketing Authorization 
Angina  Beta-blocker/HCN Channel blocker  2015 
COPD 
LABA/LAMA 2013 
ICS/LABA 2013 
ICS/LABA/LAMA 2017 
Dyslipidaemia/Atherosclerosis 
Statin/Cholesterol absorption inhibitor 2004 
Statin/Niacin 2008 
Statin/Aspirin 2004 
DP1 anti-flushing/Niacin 2008 
Heart failure 
Beta-blocker/ACEI  2015 
Beta-blocker/HCN Channel blocker 2015 
ARB/Diuretic  1998 
ACEI/Diuretic  1997 
HIV 
NRTI/NRTI 1998 
PI/PI 2001 
NRTI/NRTI/NRTI 2000 
NRTI/NRTI/NNRTI 2007 
NRTI/NRTI/Integrase inhibitor/Booster 
of integrase inhibitor 2013 
Hypertension  
ACEI/CCB 2008 
ACEI/Diuretic  1997 
ACEI/Beta-blocker  2015 
ARB/CCB  2007 
ARB/Diuretic  1998 
CCB/Diuretic  2013 
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ARB/CCB/Diuretic  2009 
ACEI/CCB/Diuretic  2014 
ACEI/CCB/Statin  2015 
ARB/Diuretic/CCB/Beta-blocker - 
Osteoporosis Bisphosphonates/Cholecalciferol  2005 
Post myocardial infarction 
Aspirin/Thienopyridines  2010 
Beta-blocker/ACEI  2015 
Type II diabetes 
Biguanide/Sulfonylurea 2016 
Biguanide/Glitazon 2003 
Sulfonylurea/Glitazon 2006 
Biguanide/DPP-4 Inhibitor 2007 
Glitazon/DPP-4 Inhibitor 2013 
Biguanide/Glinid 2008 
Biguanide/Glifozin 2014 
DPP-4 Inhibitor/Glifozin 2016 
ACEI = angiotensin converting enzyme inhibitors; ARB = angiotensin receptor blockers; CCB = 
calcium channel blockers; COPD = chronic obstructive pulmonary disease; DPP-4 = dipeptidyl 
peptidase-4; HIV = human immunodeficiency virus; ICS = inhaled corticosteroid; LABA = long-acting 
beta2 agonist; LAMA = long-acting muscarinic antagonist; NNRTI = non-nucleoside reverse 
transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor. 
Recently, FDCs have achieved a key role in management of hypertension due to the fact that 
most patients need more than two drugs to keep their blood pressure under control, as shown both 
in clinical trials and in real practice [77]. In 2018, European Society of Hypertension (ESH) and 
European Society of Cardiology (ESC) published guidelines for the management of hypertension 
[78]. In this document is stated that therapy with FDCs can be considered in both first and second-
line therapies for the attainment of the recommended value of <140/90 mmHg for blood pressure. 
Antihypertensive combination drug therapy offers advantages over single drug therapy, partly 
due to the different sites of actions of each drug and partly due to a lower risk of adverse events. This 
combination therapy is also important for patients to take their medications properly and continue 
to take them in long-term treatment. This approach proved to be effective also cost-wise. Indeed, 
Sherrill et al., in a comparative meta-analysis on health care costs of hypertension management, 
showed that yearly all-cause total costs were reduced by approximately 2039 dollars in the fixed 
combination group vs free combination and there was a reduction of about 709 dollars in 
hypertension and cardiovascular-related costs [79].  
Any drug from the following classes is proposed for four kind of two-drug FDCs: angiotensin 
converting enzyme inhibitors and calcium channel blockers, angiotensin converting enzyme 
inhibitors and diuretics, angiotensin receptor blocker and calcium channel blockers and angiotensin 
receptor blocker and diuretics. Moreover, also the combinations of angiotensin converting enzyme 
inhibitors with beta-blockers and calcium channel blockers with diuretics, are available (Table 3).  
It is now about 15 years since the concept of the polypill (defined as the combination usually of 
3, 4 or more drugs in single tablet or capsule) has been proposed to further encourage adherence to 
the treatment of NCDs, in particular cardiovascular diseases [80]. On this basis, triple fixed 
combinations have been developed for hypertension treatment (i.e., valsartan, amlodipine and 
hydrochlorothiazide) and for the human HIV type 1 infection [81] (Table 3). The newest therapeutic 
approach is represented by a quadruple fixed dose combination—the so-called quadpill—which has 
been approved for hypertension (i.e., irbesartan, amlodipine, hydrochlorothiazide and atenolol) and 
HIV virus (i.e., emcitarabine, tenofovir, elvitegravir and cobicistat) treatment [82–84]. Further 
examination of the quadpill concept is needed to investigate effectiveness against usual treatment 
options and longer term tolerability [85]. 
Some issues should be carefully taken into account when designing and developing 
formulations based on FDCs. First of all, the combination of drugs in one formulation hamper the 
tuning of the dose, making a patient centric approach more difficult. Moreover, the design of the drug 
delivery form must consider biopharmaceutical issues, as well as the pharmacokinetics, of each active 
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substance, sometimes requiring a controlled release. In addition, for each active substance, chemical 
and physical stability must be assured, also considering the compatibility with the formulation 
technologies as well as with the used excipients. Indeed, a formulation procedure/pharmaceutical 
form suitable for a specific active substance can result disadvantageous for another. Finally, 
interaction among active substances and eventual physical-chemical incompatibility should also be 
investigated. These issues generally result also in higher development and manufacturing costs. 
Different technological approaches have been successfully employed for manufacturing FDCs. 
Among them, the most intuitive approach is the coencapsulation of different solid drugs into hard 
gelatin capsules [86]. This approach can be also performed extemporaneously in clinical practice by 
pharmacists. For marketed FDCs, other technological approaches used to prepare oral formulations 
with a single active substance, such as direct compression, dry granulation, spray drying and wet 
granulation to create tablets, powders and capsules, have been used [87]. In this case, chemical-
physical incompatibility between the co-encapsulated actives must be evaluated during the 
formulation development. Alternatively, the multilayer tablet technology address incompatibilities 
of actives by compressing granules of two or more actives as different layers in one tablet. In the case 
of incompatible actives, layers of non-functional placebo have been used to avoid the interaction 
between actives present into the other layer [8]. It is worthy of note that, in this technology, the solid 
state of the active is a mandatory requisite. In this context, an innovative technology named 
UnigelTM, which is able to coencapsulate different dosage forms in soft capsules, has been 
developed. This technology allows overcoming incompatibility among components and is suitable 
for actives at solid, liquid and semisolid state, also maintaining the benefits of soft gelatin capsules. 
Furthermore, there is the risk that the final dose form becomes too sizeable, impeding oral 
administration [88]. This is particularly true for subjects suffering from dysphagia or any other 
condition that makes difficult to swallow tablets. These are common conditions in the geriatric and 
paediatric population. This could be solved via the formulation of multi-particulate, oral fast 
dissolving dosage forms [89] or 3D printing technology, which will be addressed with more detail in 
this review. Finally, the co-crystallization of drugs can lead to formation of amorphous complexes 
with solubility characteristics different respect than the naked drug [90]. Thus, different dissolution 
rate of co-precipitated drugs should be taken into account when designing FDCs, for example, for 
oral administration. 
Several studies showed that FDCs can improve medication adherence by about 25% thanks to 
the reduction of pill burden and the consequential simplification of medication management [72]. 
3.3. Orodispersible Dosage Forms 
Another strategy that can be adopted to improve adherence to therapeutics is the design of 
delivery systems able to overcome the limitation of conventional oral liquid and solid dosage forms. 
Liquids (i.e., syrups, suspensions and solutions) are very flexible in dosing and can be easily 
swallowed by the patient. However, the dose accuracy is strongly affected by the type of measuring 
device used by the patient (e.g., spoon, syringe) and the risk of misdosing is high due to incorrect 
handling [91]. Therefore, tablets and capsules are the most commonly used dosage forms. However, 
they are more difficult to swallow by children and older adults, especially when their shape and size 
have not been properly optimized.  
To solve these criticisms and improve patients’ adherence, orodispersible dosage forms (ODx) 
can be a valid technological solution [92]. An ODx is defined as a dosage form intended to be placed 
in the mouth where they rapidly liberate the loaded API producing a fine suspension or solution in 
the saliva that can be easy-to-swallow by the patient.  
By a technological point of view, two different classes of ODx are available on the market as 
medicinal products: orodispersible tablets (ODT) and orodispersible films (ODF). Similar to 
conventional tablets in organoleptic properties, ODT are designed to disintegrate in less than three 
minutes after the contact with saliva [93]. Specific production technologies are used to permit the fast 
disintegration of the ODT—freeze-drying (e.g., Zydis®), moulding or direct compression (e.g., 
Nurofen FlashTab®) of specific excipients are some of the technologies applied in the industrial 
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production of ODT. The ODF (e.g., Zuplenz®, Risperidon HEXAL SF, Rabestrom®) is thin strips of 
plasticized hydrocolloids or blends that are obtained by a solvent casting technique or hot melt 
extrusion [92]. Such technologies allow producing in industrial-scale laminates that are properly cut 
in diverse shapes to obtain the different strengths of the same formulation. The formulative space of 
ODF (<200 mg) is limited by the reduced size (e.g., 2 × 3 cm2) and thickness (<350 µm). In this context, 
the selection of ODF matrix components results very critical to the production of laminate with 
proper mechanical properties [94,95]. 
Both ODT and ODF require specific types of machinery (e.g., freeze drier, solvent casting) and 
packaging (e.g., moisture protecting packaging) to be produced. Consequently, the production costs 
of ODT/ODF are higher than conventional tablets and capsules and, therefore, their economic 
sustainability may be acceptable to market only for specific API or when a significant advantage in 
terms of bioavailability or patient adherence is expected.  
Contrary to what is expected from fast dissolving dosage forms, the use of an ODx instead of a 
conventional immediate release dosage form does not affect generally the bioavailability of the API. 
Indeed, the resistance time in the buccal cavity and oesophagus of the API suspension/solution is too 
short to sustain a significant drug permeation through the mucosae. Only in the case of selegiline, a 
significant improvement of its bioavailability was reported [96].  
Since ODx are easy-to-swallow without drinking or chewing, they do not require water for the 
medicine’s administration and, therefore, they are better accepted by travellers and bedridden or 
non-cooperative patients. Their use is also related to a reduced likelihood of suffocation or choking. 
Moreover, they are well-accepted by who is not able to take or swallow tablets or capsules. 
Swallowing problems can be due to psychological (e.g., fear), physiological (e.g., dysphagia) and 
iatrogenic causes [92]. Difficulties in swallowing medicines are particularly relevant in children, older 
adults [91] and patients with mental health disorders due to a variety of causes such as psychiatric 
medication side effects or comorbid neurologic conditions [97]. They strongly impact on the 
adherence of patients [37]. Consequently, the advantages of ODx as patient centric pharmaceutical 
drug products are mostly due to the high acceptability by the patient. Indeed, the patient’s adherence 
is generally improved with respect to conventional solid dosage forms [92,98]. For example, the 
olanzapine ODx show a comparable efficacy and safety profile with respect to conventional solid 
dosage forms but they are superior in terms of adherence and patient preference [99,100]. 
However, ODx acceptability is strongly influenced by the taste sensation after the dissolution of 
the dosage forms in the mouth [53]. Indeed, a proper strategy to taste-making is needed to cover the 
unpleasant taste of API. However, it is not an easy task due to the small formulative space of ODx 
and the existing differences in the taste preference among children, adult and geriatric populations 
[89]. Moreover, the use of moisture protective packaging that cannot be easy-to-open by older people 
can also limit the acceptability of ODx. Unlike ODT, the ODF may be difficult to handle by older 
patients with poor manual dexterity due to their shape and their thickness [91]. 
3.4. Multi-Particulate Formulations 
Multi-particulate dosage forms are multiple unit systems of mini-tablets or pellets that are filled 
into capsules, compressed into tablets or used individually. By offering great design flexibility by 
combining units with different drugs and/or with different release profiles, multi-particulate 
formulations are good candidates for personalized treatments. Adaptation of the dose, like the 
administration of an amount of pellets based on body weight, is a clear advantage for the paediatric 
population. Multi-particulate formulations are also useful for the design of FDCs since individual 
dosage units containing different drugs can be combined in the final product [101]. Despite the 
promise hold by multi-particulate formulations these dosage forms are not yet a well-established 
platform mainly due to manufacture and administration constrains, such as weight control, content 
uniformity and handling by patients. The impact on adherence has not been yet studied even though 
higher acceptability and capacity to swallow mini-tablets over syrup has been demonstrated in the 
paediatric population [102,103]. 
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3.5. Topical Formulations 
The range of topical vehicles available for the treatment of the different skin diseases is quite 
large and is presented in distinct physical forms, mainly liquid and semisolid. These can be 
hydrophilic, lipophilic or bi-phasic products. Topical vehicles can vary substantially regarding 
mechanical and sensory properties which can impact their use by patients and satisfaction with 
treatment [104]. Innovations in topical treatments are linked not only to the discovery of new drugs 
but also to the reformulation of vehicles of already-in use APIs (such as diclofenac salts and the 
association of calcipotriol and betamethasone) in order to improve administration, bioavailability, 
ease of use and adherence. Topical vehicles, like foams, emulgels and oleogels, are some examples 
[105] of what is, at present, available on the pharmaceuticals market. Satisfaction with topical 
treatment has been already associated with improved adherence [106] which justifies the investment 
in the drug product design. The impact of the topical vehicle on adherence has been, however, seldom 
investigated. In clinical practice, one possible way to meet patients’ preferences for topical vehicles is 
to allow them to try vehicle samples before establishing the treatment plan. Pharmaceutical 
compounding can also be an important strategy to obtain individualized medicines that are not 
available on the market. From the industrial point of view, patients’ preferences have to be considered 
and prioritized to achieve a universal drug product for dermatological patients. 
3.6. 3D Printing 
In the last decade, the applications of 3D-printing to the pharmaceutical field have risen and 
different technological approaches are available in the literature for preparing medicines tailored to 
the clinical needs of the patient. With respect to previously discussed patient centric pharmaceutical 
dosage forms, the 3D-printing is more versatile and flexible in dosing than API and provides 
personalized treatment to a single patient according to his/her needs. Indeed, most of the investigated 
printing technologies can be applied not only at the industrial-scale level but also in a pharmacy 
setting or, potentially, at a patient’s home. In this optic, the most promising technologies are those 
based on a binder jetting (e.g., inkjet printing) or the material extrusion [e.g., fusion deposition 
modelling (FDM); semisolid extrusion (SSE), hot melt ram extrusion (HMRE)] [107–109]. 
Such technologies have been suitable for preparing FDCs [110–113] or to load nanosystems able 
to modify the release kinetics of the drug substance [114]. For example, Khaled and coworkers 
provide a proof-of-concept of a 3D-printed FDC dosage form containing up to five APIs with different 
release profiles (i.e., acetylsalicylic acid, atenolol, hydrochlorothiazide, pravastatin, ramipril). 
Inkjet printing is based on the deposition of the corrected dose of API on an edible substrate as 
solution or suspension. The substrate, which is generally made of water-soluble polymers (e.g., 
polysaccharides, cellulose derivatives), can be easily cut and handled by the patient [107,115]. 
Moreover, the inkjet printing can be useful to prepare innovative medicinal products that combine 
the drug-loaded dosage forms and all the information needed by the patient for proper use. For an 
example, modulating the deposition design of drug-loaded fluid, Edinger and coworkers were able 
to prepare ODF in which the drug was printed as quick-response (QR) code that encodes for 
information relevant for the patient and the health professionals regarding the medicinal product 
[116]. Since the QR code can be read by a common smartphone, such an approach may be a valid 
strategy to prevent misusing or medication errors in the future. However, several parameters can 
impact on the quality of drug product made by inkjet 3D printing. For an example, the 
solubility/dispersibility of the drug in the fluid, the fluid viscosity, the porosity and the mechanical 
properties of the edible substrate, other than their possible interaction and compatibility are only a 
few aspects that have to be investigated during the formulation studies. Especially for poorly soluble 
drugs, the composition of drug-loaded fluid should avoid the drug sedimentation which is the main 
cause of dose inaccuracy but should maintain the viscosity in a range acceptable for printing [108]. 
Moreover, several parameters (e.g., evaporation time, droplet size formation) have to be set-up to 
print homogenously the drug onto the subtract [117]. 
3D printing technologies based on material extrusion are also widely studied for tailoring the 
drug product according to the patients’ needs. Based on the preparation technique used, the extruded 
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materials can be solid (e.g., FDM, HMRE) or semisolid (e.g., SSE). Moreover, the extruded material 
can be pre-formed filaments (e.g., FDM) or extemporaneously prepared (e.g., HMRE, SSE). Unlike 
binder jetting technologies, material extrusion ones do not require a preformed film onto the drug is 
deposed but the extruded material is directly printed in the designed dose and geometry. In 
particular, the shape of the dosage forms can be easily modified to improve the patient acceptability 
[118]. As a consequence, a future application of 3D printing technologies to the clinical practice will 
be advantageous to tailor both the drug dose and the morphological properties of the dosage form 
according to the patient needs, improving therapy adherence. In addition, the biopharmaceutical 
properties of the printed product can be custom-made by changing the formulation composition. 
Different kinds of pharmaceutical-grade polymers have already been tested for FDM 3D printing 
applications [119]. The design of multi-compartment devices, able not only to delivery FDCs [113], 
[112] but also to control their release kinetics to maximize the drug bioavailability, can be achieved 
[120]. However, although FDM technology is very promising in an industrial-scale, its application to 
pharmacy setting or at patient home is limited by the unavailability on the market of drug-loaded 
filaments to prepare the medicinal product and tailor the dose strength. In this context, SSE and 
HMRE technologies seem more versatile and do not require high temperature to complete the 
printing process [107]. As well as FDM 3D printing, SSE and HMRE technologies permit to produce 
fixed combination and to control of drug release kinetics modulating the composition and the 
geometry of extruded materials [107]. However, no pre-formed filaments are needed since the 
extruded material is a paste for SSE 3D printing [113] and a solid mixture of plasticized low-melting-
point components for HMRE 3D printing [109]. For both technologies, the preparation method 
consists in the mixing of the API and other components with a mortar and pestle, in the loading in 
the extruder and in the printing of the product in the designed geometry. In the case of SSE 
technology, a solvent evaporation step is also required after the printing to eliminate all the residue 
of aqueous or organic solvents used during the preparation process. Considering that HMRE 3D 
printing does not require liquids in the preparation process, this technology is also promising to print 
single dosage forms directly on the packaging material, which further simplifies the preparation 
process for a pharmacy setting. Although very promising and in continuous improvement, 
regulatory concerns remain a major issue in the roll-out of 3D technology in manufacturing 
pharmaceutical products. Indeed, unlike medical devices for which regulatory agencies have started 
to release guidance, the production of medicinal products by 3D-printing is far to be properly 
regulated due to the novelty of this technological application. Only in 2015 did the FDA authorize 
the first industrial medicinal product (Spritam®) produced by 3D-printing. Although the current 
regulatory framework on industrial production/compounding of medicinal products is flexible 
enough to be applicable to 3D technologies, the regulatory agencies are still facing important 
challenges in the definition of proper standards based on the peculiar features of 3D-printed 
medicines to assure their quality throughout the manufacturing and distribution [121]. Regardless of 
these challenges, the application of 3D printing technologies is promising for the preparation of 
patient centric pharmaceutical drug product. On one side, the possibility to print FDCs may be 
advantageous to simplify the regimen of polypharmacy patients, such as the elderly [113]. On the 
other side, 3D-printing technologies permit to design the shape of the dosage forms according to the 
patient needs. For dermal medicinal products, it permits the medicine application area to be adapted 
to the skin surface [122]. Moreover, it could also be advantageous to prepare children-friendly shape 
(e.g., stars, flowers) to improve adherence in younger patients [112]. 
4. Conclusions 
Several interventions have been proposed to increase medication adherence. When low 
adherence is ascribable to the treatment, patient centric drug product pharmaceutical design can help 
by improving the acceptability of the medicinal product. In this context, the design of the drug 
product offers the possibility to meet the needs and preferences of patients by the selection of the 
most appropriate dosage forms and formulation composition based on the peculiarities of the target 
patient population. Fixed dose combination products are greatly studied regarding promotion of 
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adherence, since they can ensure schedule simplification due to reduced dosing frequency and pill 
burden. Moreover, novel technologies including 3D printing bring exciting opportunities for the 
preparation of personalized medicines and could play a paramount role in the near future. Even if 
PCDPD may not completely resolve complex issues contributing to the problem of nonadherence, it 
is a promising idea to be taken into account in a global strategy to promote adherence to medication.  
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